Par Drugs And Chemicals Ltd. Share Price

Life has announced the launch of three new products

Life Insurance Corporation of India (LIC) is all set to launch three new products, LIC’s New Jeevan Dhara – II, LIC’s Health Shield and LIC’s New Cancer Cover. These products will cater to domestic market and will be available for sale with effect from October 19, 2026. LIC’s New Jeevan Dhara - II is a Non-Par, Non-Linked, Individual, Savings, Deferred Annuity Plan, LIC’s Health Shield is a Non-Par, Non-Linked, Health, Individual, Pure Risk Plan, while LIC’s New Cancer Cover is a Non-Par, Non-Linked, Health, Individual, Pure Risk Plan. Impact : The introduction of these plans directly addresses long-standing challenges regarding profit margins, product mix diversification, and demographic reach. View : This announcement signals to the market that LIC is aggressively addressing its structurally low Value of New Business (VNB) margins, which has historically been a major pain point for analysts.

🔥 2026 ke Smallcap Superstars! 🚀 GROWTH

🔥 2026 ke Smallcap Superstars! 🚀 Kuch Stocks Ne Diya 249% Tak Return! 2026 mein smallcap stocks ne investors ko shandaar returns diye hain! Infrastructure, technology aur manufacturing sectors ke kuch stocks ne zabardast rally dikhayi hai. 📈 📊 Nifty Smallcap 250 ke Top 10 Performers YTD Returns as of 25 September 2026 🥇 #WelspunCorp — +248.8%

Ujjivan Small Finance Bank Operating Performance

Ujjivan Small Finance Bank Ltd

SRIT India IPO: Financial Review of company

SRIT India is launching its initial public offering between September 28 and 30, aiming to raise 218 crore at a valuation of 835 crore. The company provides IT services and software solutions primarily to government offices. Currently, it holds an order book of approximately 1,200 crore, which is 150% of its total valuation. While the company displays improving EBITDA margins and a P/E ratio of approximately 19, there are notable concerns. Management has not disclosed the intended use for 40% of the IPO proceeds, a red flag for operational transparency. Furthermore, despite revenue growth, the company has struggled with operational efficiency, failing to convert its significant order backlog into proportional bottom-line growth. While valuation appears reasonable at par, the P/B ratio of 2 indicates that the stock is not deeply undervalued compared to peers. I am positive regarding potential listing gains and short-term performance. However, long-term viability remains uncertain until execution consistency improves. Investors should exercise caution regarding the undisclosed capital allocation.

Waaree Energies ko 2 GW ka solar module order mila hai.

Suzlon ka stock ek time par ₹60 ke upar tha, and now crash